Table 1 Demographic and clinical characteristics of the fMRI and BAT samples according to rs6295 (−1019C/G HTR1A) genotype

From: The functional −1019C/G HTR1A polymorphism and mechanisms of fear

 

Genotype

Differences (CC vs GG)

 

CC

CG

GG

 

Genetic-BAT-sample (N=245)

 N

60

120

65

χ2/F

P

 Female (n (%))

42 (70.21)

82 (68.33)

54 (83.08)

2.99a

0.08

 Age (years)

36.38 (10.88)

35.58 (11.50)

35.46 (10.23)

0.24

0.63

 Clinical characteristics at baseline

SIGH-A total

24.53 (5.04)

23.71 (5.23)

24.46 (5.55)

0.01

0.94

PAS total

26.96 (9.64)

26.14 (9.96)

28.23 (9.33)

0.57

0.45

CGI

5.17 (0.74)

5.18 (0.72)

5.29 (0.61)

1.09

0.30

ASI total

31.15 (9.96)

30.51 (11.60)

32.28 (12.61)

0.31

0.58

BDI II total

16.19 (8.82)

16.56 (8.24)

15.87 (9.02)

0.04

0.84

MI7

2.07 (0.92)

1.93 (0.99)

1.92 (0.99)

0.69

0.41

 

Genotype

Differences (CC/CG vs GG)

 

CC

CG

GG

 

Genetic-BAT-treatment-sample (N=171)

 N

43

85

43

χ2/F

P

 Female (n (%))

29 (67.44)

57 (67.06)

34 (79.07)

2.17a

0.34

 Age (years)

36.28 (11.31)

36.60 (12.09)

33.28 (9.40)

1.31

0.27

 Clinical characteristics at baseline

SIGH-A total

25.09 (5.37)

23.62 (5.07)

25.19 (5.76)

1.74

0.18

PAS total

26.39 (9.18)

25.78 (9.85)

29.33 (9.37)

2.04

0.13

CGI

5.26 (0.76)

5.16 (0.72)

5.28 (0.63)

0.46

0.63

ASI total

32.81 (9.95)

30.72 (11.35)

33.12 (12.62)

0.84

0.43

BDI II total

16.67 (9.00)

16.34 (8.56)

15.51 (9.14)

0.21

0.81

MI7

1.97 (0.89)

1.83 (0.88)

1.87 (0.89)

0.35

0.70

 Clinical characteristics at post-treatment

SIGH-A total

13.65 (7.89)

11.78 (7.57)

12.60 (6.90)

0.89

0.41

PAS total

13.68 (8.93)

14.21 (9.52)

14.18 (8.14)

0.05

0.95

CGI

3.42 (0.85)

3.46 (1.11)

3.40 (1.00)

0.06

0.94

ASI total

17.23 (10.36)

15.86 (10.42)

16.47 (10.04)

0.26

0.77

BDI II total

8.49 (8.36)

8.62 (7.99)

8.44 (8.26)

0.01

0.99

MI7

1.53 (0.68)

1.29 (0.49)

1.47 (0.68)

2.43

0.09

 

Genotype

Differences (CC vs GG)

 

CC

CG

GG

 

Genetic-fMRI-treatment-sample (N=39)

 N

9

21

9

F

P

 Female (n (%))

7 (77.78)

14 (66.67)

5 (55.56)

1.00a

0.62

 Age (years)

30.11 (11.47)

37.67 (10.01)

36.11 (7.57)

1.76

0.20

 Clinical characteristics at baseline

SIGH-A total

22.89 (4.68)

23.62 (5.34)

26.22 (5.93)

1.75

0.20

PAS total

22.99 (6.72)

24.19 (9.33)

31.90 (7.80)

6.74

0.02

CGI

5.00 (0.71)

5.38 (0.59)

5.67 (0.50)

5.33

0.04

ASI total

30.44 (6.50)

29.14 (9.08)

36.00 (11.41)

1.61

0.22

BDI II total

14.00 (7.63)

16.05 (7.40)

18.67 (11.51)

1.03

0.33

MI7

1.84 (0.71)

1.84 (0.93)

1.65 (1.00)

0.22

0.65

 Clinical characteristics at post-treatment

SIGH-A total

9.78 (3.99)

12.38 (6.66)

13.44 (9.38)

1.16

0.29

PAS total

9.15 (5.28)

13.57 (8.96)

18.54 (8.79)

7.54

0.01

CGI

3.22 (0.97)

3.62 (1.24)

3.78 (0.67)

2.00

0.18

ASI total

13.00 (7.81)

15.05 (7.41)

19.11 (11.94)

1.65

0.22

BDI II total

4.78 (6.40)

9.67 (6.16)

9.89 (11.17)

1.42

0.25

MI7

1.45 (0.71)

1.24 (0.38)

1.20 (0.41)

0.82

0.38

  1. Abbreviations: ASI, Anxiety Sensitivity Index; BDI II, Beck Depression Inventory II; CGI, Clinical Global Impressions Scale; PAS, Panic and Agoraphobia Scale; MI7, 7-day version of the Movement Inventory (accompanied); SIGH-A, Hamilton Anxiety Scale.
  2. aPearson's Chi-square.
  3. Means (s.d.) except where noted. Due to missing values, MI7 scores were available in the BAT total sample only in 229 patients (CC: 57, CG: 112, GG: 60) and in the BAT treatment group sample only in 160 patients (CC: 41, CG: 80, GG: 39).
Back to article page